![]() |
ROCKVILLE, Md., Aug. 26, 2024 /PRNewswire/ — I-Mab (NASDAQ: IMAB), a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that management will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024.
H.C. Wainwright 26th Annual Global Investment Conference
|
Presentation Time |
Tuesday, September 10 at 5:00 PM ET |
|
Presenters |
Sean Fu, PhD, Interim Chief Executive Officer (CEO) Phillip Dennis, MD, PhD, Chief Medical Officer (CMO) |
|
Webcast link |
|
|
Meetings |
One-on-one and small group meetings: September 9 – 10, 2024 |
|
Management |
Sean Fu, PhD, Interim CEO Joe Skelton, Chief Financial Officer (CFO) Phillip Dennis, MD, PhD, CMO Tyler Ehler, Senior Director, Investor Relations |
The webcast will also be available under “Event Calendar” on I-Mab’s IR website
at https://ir.i-mabbiopharma.com/
For more information, please contact your H.C. Wainwright representative.
About I-Mab
I-Mab (NASDAQ: IMAB) is a US-based, global, clinical-stage biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer. I-Mab has established operations in Rockville, Maryland. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
For more information, please contact:
Tyler Ehler
Senior Director, Investor Relations
IR@imabbio.com



Đề xuất
GovWare 2026 closes with a clear focus on securing AI that can act
Trip.com Malaysia secures win at Travel Daily Media Travel Trade Excellence Awards 2026 – Malaysia
ECI Group announces the successful start-up and operation of first HPPE plant
AMPERA and Berto Announce Proposed Business Combination to Accelerate Advanced Energy Technology Development and Commercialization
Mexican Influencer Max y Noelia Highlights Open Trade at the 9th CIIE While Touring Five APEC Economy Pavilions
Asia Pacific accounts for a third of the world’s fraud networks as identity fraud grows more complex: Sumsub